Tetrathiomolybdate anticopper therapy for Wilson's disease inhibits angiogenesis, fibrosis and inflammation.
The need for agents to lower body copper in Wilson's disease, a disease which results from copper toxicity has been the driving force for the development of the effective anticopper drugs penicillamine, trientine, zinc, and now tetrathiomolybdate (TM). Because of its rapid action, potency, and safety, TM is proving to be a very effective drug for initial treatment of acutely ill Wilson's disease patients. Beyond this, TM has antiangiogenic effects, because many proangiogenic cytokines require normal levels of copper. This has led to use of TM in cancer, where it is generally effective in animal tumor models, and has shown efficacy in preliminary clinical studies. Most recently, it has been found that TM has antifibrotic and antiinflammatory effects through inhibition of profibrotic and proinflammatory cytokines.
Brewer
G J
GJ
Department of Human Genetics and Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA. brewergj@umich.edu
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D015913:Chelation Therapy; D003300:Copper / Q000378:metabolism*; D016207:Cytokines / Q000378:metabolism; D005355:Fibrosis / Q000378:metabolism*; D006527:Hepatolenticular Degeneration / Q000188:drug therapy*; D006801:Humans; D007249:Inflammation / Q000378:metabolism*; D008982:Molybdenum / Q000627:therapeutic use*
D020533:Angiogenesis Inhibitors; D016207:Cytokines; D003300:Copper; D008982:Molybdenum; C020809:tetrathiomolybdate